Novo Nordisk

NVO

Market cap $174B

Maziar Mike Doustdar, CEO of Novo Nordisk, says AI partnership with OpenAI will speed drug discovery and delivery, boost accuracy and strengthen confidence in Wegovy despite rising competition.

ASML reported solid 4Q25 results and record bookings due to strong AI demand for DRAM and advanced logic, and FY2026 guidance is above consensus. Adyen reported December quarter results slightly below consensus expectations, with net revenue growing 19% y/y. For the Baird Chautauqua International Growth Fund, 60% of companies that reported earnings during the quarter were in line with or exceeded consensus estimates.

Novo Nordisk and Novartis deepened their ties to AI companies on Tuesday.

Novo Nordisk faces rising pressure as LLY launches Foundayo, a rival obesity pill, challenging Wegovy despite data suggesting NVO's edge in efficacy.

Novo Nordisk reached an all-time high of $148.15 in June 2024, when market participants were widely optimistic about the prospects of NVO's new semaglutide drug for weight management, Wegovy. After a long series of disappointments and missteps, Novo Nordisk closed at $37.98 per share as of April 13th, the equivalent of a ~75% drawdown in less than 24 months. Even though market expectations have been revised lower multiple times, Novo Nordisk continues to generate a significant amount of free cash flow while being supported by a strong 'AA' balance sheet.

Novo Nordisk is working with OpenAI on a broad deal that will use artificial intelligence to more quickly develop new medications as well as help train its workforce.

Novo's OpenAI partnership will help it discover new therapies bringing them to market faster.

Novo Nordisk (NYSE: NVO), the company behind the blockbuster diabetes and weight-loss drug Ozempic, has announced a strategic partnership with OpenAI.

The Danish drugmaker becomes the latest major pharmaceutical company to embed AI across its entire drug development pipeline, from discovery to commercial operations. Novo Nordisk (NYSE:NVO), the Danish pharmaceutical giant best known for its diabetes and obesity treatments, has formed a partnership with OpenAI that will apply the artificial intelligence company's most advanced capabilities.

Novo Nordisk on Tuesday announced a partnership with OpenAI to deploy artificial intelligence across its business, spanning drug discovery, manufacturing and commercial operations, as the Danish drugmaker looks to sharpen its competitive edge in the fast-growing obesity drug market. The company said the collaboration would leverage OpenAI's technology to analyse complex datasets, identify promising drug candidates and improve efficiency across manufacturing, supply chains and distribution.